Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
16 Diciembre 2024 - 3:30PM
Neuronetics, Inc. (NASDAQ: STIM) (the “Company”) today announced
the granting of inducement awards to new employees as described
below. In accordance with NASDAQ Listing Rule 5635(c)(4), these
awards were approved by the Compensation Committee of the Company’s
Board of Directors and were made as material inducements to the
recipients’ employment with the Company. In all cases, vesting is
subject to the recipient’s continued service with the Company
through the applicable vesting date, and the awards are subject to
the terms of the Company’s 2020 Inducement Incentive Plan.
Performance restricted stock units
(“PRSUs”)
Name |
Number of PRSUs |
Vesting Date |
Bill Leonard |
100,000 |
December 31, 2025 |
Andy Crish |
60,000 |
December 31, 2025 |
Geoff Grammer |
60,000 |
December 31, 2025 |
Peter Willett |
60,000 |
December 31, 2025 |
25% of the award will be attained if the Company achieves cash
flow breakeven for the fiscal quarter ended June 30, 2025, 50% of
the award will be attained if the Company achieves cash flow
breakeven for the fiscal quarter ended September 30, 2025, and 25%
of the award will be attained if the Company achieves cash flow
breakeven for the fiscal quarter ended December 31, 2025.
Restricted stock units (“RSUs”)
Name |
Number of Inducement Plan RSUs |
Vesting Schedule |
Bill Leonard |
100,000 |
1/3 on first anniversary of grant date; 1/3 on second anniversary
of grant date; 1/3 on third anniversary of grant date |
Bill Leonard |
100,000 |
1/3 on second anniversary of grant date; 1/3 on third anniversary
of grant date; 1/3 on fourth anniversary of grant date |
Andy Crish |
33,750 |
1/3 on first anniversary of grant date; 1/3 on second anniversary
of grant date; 1/3 on third anniversary of grant date |
Andy Crish |
33,750 |
1/3 on second anniversary of grant date; 1/3 on third anniversary
of grant date; 1/3 on fourth anniversary of grant date |
Geoff Grammer |
33,750 |
1/3 on first anniversary of grant date; 1/3 on second anniversary
of grant date; 1/3 on third anniversary of grant date |
Geoff Grammer |
33,750 |
1/3 on second anniversary of grant date; 1/3 on third anniversary
of grant date; 1/3 on fourth anniversary of grant date |
Peter Willett |
33,750 |
1/3 on first anniversary of grant date; 1/3 on second anniversary
of grant date; 1/3 on third anniversary of grant date |
Peter Willett |
33,750 |
1/3 on second anniversary of grant date; 1/3 on third anniversary
of grant date; 1/3 on fourth anniversary of grant date |
Latoya Blaylock |
24,000 |
1/3 on first anniversary of grant date; 1/3 on second anniversary
of grant date; 1/3 on third anniversary of grant date |
Latoya Blaylock |
16,000 |
1/3 on second anniversary of grant date; 1/3 on third anniversary
of grant date; 1/3 on fourth anniversary of grant date |
Annie Farley |
24,000 |
1/3 on first anniversary of grant date; 1/3 on second anniversary
of grant date; 1/3 on third anniversary of grant date |
Annie Farley |
16,000 |
1/3 on second anniversary of grant date; 1/3 on third anniversary
of grant date; 1/3 on fourth anniversary of grant date |
Thomas Harris |
24,000 |
1/3 on first anniversary of grant date; 1/3 on second anniversary
of grant date; 1/3 on third anniversary of grant date |
Thomas Harris |
16,000 |
1/3 on second anniversary of grant date; 1/3 on third anniversary
of grant date; 1/3 on fourth anniversary of grant date |
Nicole Lowry |
24,000 |
1/3 on first anniversary of grant date; 1/3 on second anniversary
of grant date; 1/3 on third anniversary of grant date |
Nicole Lowry |
16,000 |
1/3 on second anniversary of grant date; 1/3 on third anniversary
of grant date; 1/3 on fourth anniversary of grant date |
Bryce Newmann |
24,000 |
1/3 on first anniversary of grant date; 1/3 on second anniversary
of grant date; 1/3 on third anniversary of grant date |
Bryce Newmann |
16,000 |
1/3 on second anniversary of grant date; 1/3 on third anniversary
of grant date; 1/3 on fourth anniversary of grant date |
Egan Pratt |
24,000 |
1/3 on first anniversary of grant date; 1/3 on second anniversary
of grant date; 1/3 on third anniversary of grant date |
Egan Pratt |
16,000 |
1/3 on second anniversary of grant date; 1/3 on third anniversary
of grant date; 1/3 on fourth anniversary of grant date |
About Neuronetics and Greenbrook
Neuronetics, Inc. (“Neuronetics”) believes that mental health is
as important as physical health. As a global leader in
neuroscience, Neuronetics is redefining patient and
physician expectations by offering exceptional treatments that
produce extraordinary results. Neuronetics’ NeuroStar Advanced
Therapy for Mental Health is a non-drug, noninvasive treatment that
can improve the quality of life for people suffering from
neurohealth conditions when traditional medication has not helped.
In addition to selling the NeuroStar system and associated
treatment sessions to customers, Greenbrook TMS Inc. (“Greenbrook”)
operates treatment centers across the United States, offering
both NeuroStar Advanced Therapy (transcranial magnetic stimulation
or “TMS”) and Spravato® (esketamine nasal spray) for the treatment
of major depressive disorder (“MDD”) and other mental health
disorders. NeuroStar Advanced Therapy is the leading TMS treatment
for MDD in adults with more than 6.9 million treatments delivered
and is backed by the largest clinical data set of any TMS treatment
system for depression, including the world’s largest depression
outcomes registry. Spravato® is offered to treat adults with
treatment-resistant depression and depressive symptoms in adults
with MDD with suicidal thoughts or actions. Greenbrook has provided
more than 1.68 million treatments to over 51,000 patients
struggling with depression.
Investor Contact:Mike Vallie or Mark
KlausnerICR Healthcare443-213-0499ir@neuronetics.com
Media
Contact:EvolveMKD646-517-4220NeuroStar@evolvemkd.com
Neuronetics (NASDAQ:STIM)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Neuronetics (NASDAQ:STIM)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024